Home » Lonza to Partner With Teva on Biosimilars
Lonza to Partner With Teva on Biosimilars
Teva Pharmaceutical Industries and Lonza Group are establishing a joint venture to develop, manufacture and market biosimilars. Both companies plan to explore additional biosimilars opportunities outside the partnership, according to a joint statement. The companies expect to start operations in this year’s first quarter. Financial details of the agreement were not disclosed.
Drug GMP Report
Drug GMP Report
Upcoming Events
-
07May
-
14May
-
30May